WUXI BIO previously announced the sale of assets related to the Irish vaccine facility to Merck (MSD International) for a total price of approximately 0.5 billion USD. Citi released a Research Report stating that while WUXI BIO's move to divest specified overseas facilities aligns with market expectations, some may view the asset sale as a defensive action against potential geopolitical risks. The bank believes that the transaction concerning the Irish vaccine facility will not have a negative financial impact on the company and will improve its overall profitability. Citi set a Target Price of 30 HKD on WUXI BIO and gave a 'Buy' rating.